J Neurophysiol. 2003 Aug 6
Lo AC, Saab CY, Black JA, Waxman SG.
Neurology, PVA/EPVA Neuroscience Research Center, Yale University School of Medicine, and the Rehabilitation Research Center, VA Healthcare Systems, West Haven, CT, USA.
Axonal degeneration within the spinal cord contributes substantially to neurological disability in multiple sclerosis (MS).
Thus neuroprotective therapies that preserve axons, so that they maintain their integrity and continue to function, might be expected to result in improved neurological outcome.
Sodium channels are known to provide a route for sodium influx that can drive calcium influx, via reverse operation of the Na(+)/Ca(2+) exchanger, after injury to axons within the CNS, and sodium channel blockers have been shown to protect CNS axons from degeneration following experimental anoxic, traumatic, and NO-induced injury.
In this study we asked whether phenytoin, which is known to block sodium channels, can protect spinal cord axons from degeneration in mice with experimental allergic encephalomyelitis (EAE), which display substantial axonal degeneration and clinical paralysis.
We demonstrate that the loss of dorsal corticospinal tract (63%) and dorsal column (cuneate fasciculus) (43%) axons in EAE is significantly ameliorated (corticospinal tract: 28%; cuneate fasciculus: 17%) by treatment with phenytoin.
Spinal cord compound action potentials (CAP) were significantly attenuated in untreated-EAE, whereas spinal cords from phenytoin-treated EAE had robust CAPs, similar to those from phenytoin-treated control mice.
Clinical scores in phenytoin-treated EAE at 28 days were significantly improved (1.5, i.e. minor righting reflex abnormalities) compared to untreated EAE (3.8, i.e. near-complete hindlimb paralysis).
Our results demonstrate that phenytoin has a protective effect in vivo on spinal cord axons, preventing their degeneration, maintaining their ability to conduct action potentials, and improving clinical status in a model of neuroinflammation.